InvestorsHub Logo
Followers 188
Posts 22523
Boards Moderated 0
Alias Born 08/14/2011

Re: None

Thursday, 06/20/2024 10:10:35 AM

Thursday, June 20, 2024 10:10:35 AM

Post# of 648993
IBRX $7.31 + 17% 09:45 AM EDT,06/20/2024 (MT Newswires) -- ImmunityBio (IBRX) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses.

The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or without papillary tumors, according to ImmunityBio.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.